Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Long-Term Debt Repayments (2023 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Long-Term Debt Repayments for 3 consecutive years, with $5.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Long-Term Debt Repayments rose 41.81% to $5.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $19.9 million, a 54.4% increase, with the full-year FY2025 number at $19.9 million, up 54.4% from a year prior.
  • Long-Term Debt Repayments was $5.4 million for Q4 2025 at Rhythm Pharmaceuticals, down from $5.6 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $5.6 million in Q3 2025 to a low of $1.3 million in Q2 2023.
  • A 3-year average of $3.4 million and a median of $3.2 million in 2024 define the central range for Long-Term Debt Repayments.
  • Peak YoY movement for Long-Term Debt Repayments: surged 127.64% in 2024, then surged 41.81% in 2025.
  • Rhythm Pharmaceuticals' Long-Term Debt Repayments stood at $2.6 million in 2023, then skyrocketed by 47.94% to $3.8 million in 2024, then soared by 41.81% to $5.4 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Long-Term Debt Repayments are $5.4 million (Q4 2025), $5.6 million (Q3 2025), and $4.3 million (Q2 2025).